Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H56N6O9S |
| Molecular Weight | 820.994 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1)N=C3CCCCC[C@@H]4CCC[C@H]4OC(=O)N[C@H]5CCCCC\C=C\[C@@H]6C[C@]6(NC(=O)[C@@H]7C[C@H](CN7C5=O)OC3=N2)C(=O)NS(=O)(=O)C8(C)CC8
InChI
InChIKey=BLFKRFGLQFYXDF-WAZRELCSSA-N
InChI=1S/C42H56N6O9S/c1-41(20-21-41)58(53,54)47-39(51)42-24-27(42)14-8-4-3-5-9-16-32-38(50)48-25-29(23-34(48)36(49)46-42)56-37-31(43-30-19-18-28(55-2)22-33(30)44-37)15-10-6-7-12-26-13-11-17-35(26)57-40(52)45-32/h8,14,18-19,22,26-27,29,32,34-35H,3-7,9-13,15-17,20-21,23-25H2,1-2H3,(H,45,52)(H,46,49)(H,47,51)/b14-8+/t26-,27-,29-,32+,34+,35-,42-/m1/s1
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01329913
Eight 100 mg capsules, orally, once per day for 7 days
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1263814-52-3
Created by
admin on Tue Apr 01 16:39:36 GMT 2025 , Edited by admin on Tue Apr 01 16:39:36 GMT 2025
|
PRIMARY | |||
|
59LD48P07K
Created by
admin on Tue Apr 01 16:39:36 GMT 2025 , Edited by admin on Tue Apr 01 16:39:36 GMT 2025
|
PRIMARY | |||
|
121596640
Created by
admin on Tue Apr 01 16:39:36 GMT 2025 , Edited by admin on Tue Apr 01 16:39:36 GMT 2025
|
PRIMARY | |||
|
DB15249
Created by
admin on Tue Apr 01 16:39:36 GMT 2025 , Edited by admin on Tue Apr 01 16:39:36 GMT 2025
|
PRIMARY |
ACTIVE MOIETY